Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333918 · ClinicalTrials.gov registry record · Phase 3
Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 522
- Enrollment target
NCT00333918 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 522 participants.
The verdict
NCT00333918, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 522 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment of ocular inflammation and pain in subjects who undergo cataract extraction and intraocular lens implantation.
Interventions
- DRUG bromfenac ophthalmic solution
- DRUG placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333918
The ClinicalTrials.gov registry entry for NCT00333918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 522 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bromfenac ophthalmic solution is the first listed.
NCT00333918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333918 about?
NCT00333918 is a clinical study titled "Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery". The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment of ocular inflammation and pain in subjects who undergo cataract extraction and intraocular lens implantation.
What is the current status of trial NCT00333918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 522 participants. The study started on 2006-06. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00333918?
The interventions under investigation include: bromfenac ophthalmic solution (DRUG), placebo comparator (DRUG).
Who is sponsoring clinical trial NCT00333918?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.